Dr. Reddy's Laboratories announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the U.S. market. This product is the generic equivalent of Extra-Strength Pataday® Once-Daily Relief and has been approved by the U.S. Food and Drug Administration (USFDA).

The Antihistamine eye drop is indicated for the temporary relief of itchy eyes caused by allergens like pollen, ragweed, grass, and animal hair and dander. This launch expands Dr. Reddy's existing OTC eye-care portfolio, which already includes Olopatadine Hydrochloride Ophthalmic Solution USP in 0.2% and 0.1% strengths.

Milan Kalawadia, CEO of North America Generics at Dr. Reddy's Laboratories, Inc., highlighted that this first-to-market launch demonstrates the company's capabilities in bringing store-brand equivalents of OTC brands to the U.S. market. Dr. Reddy's aims to deepen its collaboration with retail customers through this new offering.

The Pataday® brand generated approximately $69.9 million (approximately ₹582.7 crore) in U.S. sales for the 52 weeks ending December 27, 2025. Dr. Reddy's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle.